Tredano M, De Blic J, Griese M, Fournet J C, Elion J, Bahuau M
Service de Biochimie et Biologie Moléculaire, H pital d'Enfants Armand-Trousseau, Paris, France.
Clin Chem Lab Med. 2001 Feb;39(2):90-108. doi: 10.1515/CCLM.2001.018.
Pulmonary surfactant is a multimolecular complex located at the air-water interface within the alveolus to which a range of physical (surface-active properties) and immune functions has been assigned. This complex consists of a surface-active lipid layer (consisting mainly of phospholipids), and of an aqueous subphase. From discrete surfactant sub-fractions one can isolate strongly hydrophobic surfactant proteins B (SP-B) and C (SP-C) as well as collectins SP-A and SP-D, which were shown to have specific structural, metabolic, or immune properties. Inborn or acquired abnormalities of the surfactant, qualitative or quantitative in nature, account for a number of human diseases. Beside hyaline membrane disease of the preterm neonate, a cluster of hereditary or acquired lung diseases has been characterized by periodic acid-Schiff-positive material filling the alveoli. From this heterogeneous nosologic group, at least two discrete entities presently emerge. The first is the SP-B deficiency, in which an essentially proteinaceous material is stored within the alveoli, and which represents an autosomal recessive Mendelian entity linked to the SFTPB gene (MIM 1786640). The disease usually generally entails neonatal respiratory distress with rapid fatal outcome, although partial or transient deficiencies have also been observed. The second is alveolar proteinosis, characterized by the storage of a mixed protein and lipid material, which constitutes a relatively heterogeneous clinical and biological syndrome, especially with regard to age at onset (from the neonate through to adulthood) as well as the severity of associated signs. Murine models, with a targeted mutation of the gene encoding granulocyte macrophage colony-stimulating factor (GM-CSF) (Csfgm) or the beta subunit of its receptor (II3rb1) support the hypothesis of an abnormality of surfactant turnover in which the alveolar macrophage is a key player. Apart from SP-B deficiency, in which a near-consensus diagnostic chart can be designed, the ascertainment of other abnormalities of surfactant metabolism is not straightforward. The disentanglement of this disease cluster is however essential to propose specific therapeutic procedures: repeated broncho-alveolar lavages, GM-CSF replacement, bone marrow grafting or lung transplantation.
肺表面活性物质是一种多分子复合物,位于肺泡内的气-水界面,具有一系列物理(表面活性特性)和免疫功能。该复合物由一个表面活性脂质层(主要由磷脂组成)和一个水相亚相组成。从离散的表面活性物质亚组分中,可以分离出强疏水性的表面活性蛋白B(SP-B)和C(SP-C)以及凝集素SP-A和SP-D,它们具有特定的结构、代谢或免疫特性。表面活性物质的先天性或后天性异常,无论是定性还是定量的,都可导致多种人类疾病。除了早产儿的透明膜病外,一组遗传性或后天性肺部疾病的特征是肺泡内充满高碘酸-希夫阳性物质。从这个异质性疾病组中,目前至少出现了两个离散的实体。第一个是SP-B缺乏症,其中一种基本上是蛋白质的物质储存在肺泡内,它是一种与SFTPB基因(MIM 1786640)相关的常染色体隐性孟德尔实体。这种疾病通常会导致新生儿呼吸窘迫并迅速致命,不过也观察到了部分或短暂的缺乏症。第二个是肺泡蛋白沉积症,其特征是混合蛋白质和脂质物质的储存,这构成了一种相对异质性的临床和生物学综合征,特别是在发病年龄(从新生儿到成年人)以及相关体征的严重程度方面。编码粒细胞巨噬细胞集落刺激因子(GM-CSF)(Csfgm)或其受体β亚基(II3rb1)的基因发生靶向突变的小鼠模型支持表面活性物质周转异常的假说,其中肺泡巨噬细胞是关键因素。除了SP-B缺乏症(可以设计出近乎一致的诊断图表)外,确定表面活性物质代谢的其他异常并不简单。然而,解开这个疾病组对于提出具体的治疗程序至关重要:反复支气管肺泡灌洗、GM-CSF替代、骨髓移植或肺移植。